QRx’s Dual Opioid Works In Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Australian specialty pharma takes aim at U.S. pain, CNS markets.
You may also be interested in...
Panel Abuses Purdue Over OxyContin
Tamper-resistant version would lead to more problems, say FDA advisors.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.